- Record: found
- Abstract: found
- Article: not found
Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes.
Bart Keymeulen
1 ,
Evy Vandemeulebroucke ,
Anette G Ziegler ,
Chantal Mathieu ,
Leonard Kaufman ,
Geoff Hale ,
Frans Gorus ,
Michel Goldman ,
Markus Walter ,
Sophie Candon ,
Liliane Schandene ,
Laurent Crenier ,
Christophe De Block ,
Jean-Marie Seigneurin ,
Pieter De Pauw ,
Denis Pierard ,
Ilse Weets ,
Peppy Rebello ,
Pru Bird ,
Eleanor Berrie ,
Mark Frewin ,
Herman Waldmann ,
Jean-François Bach ,
Daniel Pipeleers ,
Lucienne Chatenoud
Jun 23 2005
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Type 1 diabetes mellitus is a T-cell-mediated autoimmune disease that leads to a major loss of insulin-secreting beta cells. The further decline of beta-cell function after clinical onset might be prevented by treatment with CD3 monoclonal antibodies, as suggested by the results of a phase 1 study. To provide proof of this therapeutic principle at the metabolic level, we initiated a phase 2 placebo-controlled trial with a humanized antibody, an aglycosylated human IgG1 antibody directed against CD3 (ChAglyCD3).